Search results
Results from the WOW.Com Content Network
The contrast between AbbVie's performance and that of the wider market was stark, as the bellwether S&P 500 (SNPINDEX: ^GSPC) sank by a relatively steep 1.5%. Why AbbVie Stock Popped While the ...
Disappointing news from the laboratory weighed on AbbVie (NYSE: ABBV) stock as the trading week kicked off. The company had high hopes for a schizophrenia drug it was developing; however, it did ...
Shares nose-dive after clinical results from an important pipeline product come up short.
AbbVie (ABBV) misses estimates for both earnings and revenues in fourth quarter. Biosimilar competition impacts Humira sales in ex-U.S. markets. Imbruvica and Mavyret offset Humira decline.
Here's what makes AbbVie a long-term buy-and-hold dividend gold mine. Why did AbbVie's stock dip? AbbVie (NYSE: ABBV) recently dipped nearly 20% and is still down 14%, offering an enticing 3.7% ...
The Dow Jones Industrial Average was down nearly half a percent at the close, while the Nasdaq Composite Index, which contains more technology stocks, cut early losses to close just 0.2% lower ...
For premium support please call: 800-290-4726 more ways to reach us
AbbVie's earnings (ABBV) beat estimates for third-quarter 2022, while sales miss the same. Shares drop in pre-market trading after it narrows down its full-year earnings guidance.